HYNŠT, Jakub, Veronika NAVRKALOVÁ, Karol PÁL and Šárka POSPÍŠILOVÁ. Bioinformatic strategies for the analysis of genomic aberrations detected by targeted NGS panels with clinical application. PeerJ. London: PEERJ INC, 2021, vol. 9, MAR 2021, p. 1-29. ISSN 2167-8359. Available from: https://dx.doi.org/10.7717/peerj.10897.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Bioinformatic strategies for the analysis of genomic aberrations detected by targeted NGS panels with clinical application
Authors HYNŠT, Jakub (203 Czech Republic, belonging to the institution), Veronika NAVRKALOVÁ (203 Czech Republic, belonging to the institution), Karol PÁL (703 Slovakia, belonging to the institution) and Šárka POSPÍŠILOVÁ (203 Czech Republic, guarantor, belonging to the institution).
Edition PeerJ, London, PEERJ INC, 2021, 2167-8359.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30101 Human genetics
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.061
RIV identification code RIV/00216224:14740/21:00120097
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.7717/peerj.10897
UT WoS 000635103900002
Keywords in English Bioinformatic analysis; SNV/indel; CNV; Clinical application; Molecular markers; NGS; Targeted panels
Tags 14110212, 14110323, CF GEN, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 22/12/2021 16:41.
Abstract
Molecular profiling of tumor samples has acquired importance in cancer research, but currently also plays an important role in the clinical management of cancer patients. Rapid identification of genomic aberrations improves diagnosis, prognosis and effective therapy selection. This can be attributed mainly to the development of next-generation sequencing (NGS) methods, especially targeted DNA panels. Such panels enable a relatively inexpensive and rapid analysis of various aberrations with clinical impact specific to particular diagnoses. In this review, we discuss the experimental approaches and bioinformatic strategies available for the development of an NGS panel for a reliable analysis of selected biomarkers. Compliance with defined analytical steps is crucial to ensure accurate and reproducible results. In addition, a careful validation procedure has to be performed before the application of NGS targeted assays in routine clinical practice. With more focus on bioinformatics, we emphasize the need for thorough pipeline validation and management in relation to the particular experimental setting as an integral part of the NGS method establishment. A robust and reproducible bioinformatic analysis running on powerful machines is essential for proper detection of genomic variants in clinical settings since distinguishing between experimental noise and real biological variants is fundamental. This review summarizes state-of-the-art bioinformatic solutions for careful detection of the SNV/Indels and CNVs for targeted sequencing resulting in translation of sequencing data into clinically relevant information. Finally, we share our experience with the development of a custom targeted NGS panel for an integrated analysis of biomarkers in lymphoproliferative disorders.
Links
EF16_026/0008448, research and development projectName: Analýza českých genomů pro teranostiku
LM2015091, research and development projectName: Národní centrum lékařské genomiky (Acronym: NCLG)
Investor: Ministry of Education, Youth and Sports of the CR
MUNI/A/1395/2019, interní kód MUName: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VII (Acronym: VýDiTeHeMa VII)
Investor: Masaryk University, Category A
NV19-03-00091, research and development projectName: Komplexní prognostický a prediktivní panel pro pacienty s chronickou lymfocytární leukémií: nástroj sekvenování nové generace vhodný pro klinickou praxi i studium genetického pozadí průběhu choroby
Investor: Ministry of Health of the CR
PrintDisplayed: 25/4/2024 08:55